177Lu-DOTATOC

DRUG7 trials

Conditions

Carcinoid TumorGastrinomaGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumour (GEP-NET)InsulinomaNeuroendocrine Breast TumorNeuroendocrine Carcinoma MetastaticNeuroendocrine Neoplasia's (NENs)

Early Phase 1

Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)

RecruitingNCT05359146

University Hospital, Basel, SwitzerlandGastroenteropancreatic Neuroendocrine Tumour (GEP-NET), Neuroendocrine Neoplasia's (NENs)

Start: 2023-03-28End: 2025-12-31Target: 16Updated: 2024-04-19

Phase 2

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

NCT04194125

University of Warmia and MazuryNeuroendocrine Tumors

Start: 2019-02-01End: 2022-01-31Target: 25Updated: 2020-11-04

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

WithdrawnNCT04276597

Excel Diagnostics and Nuclear Oncology CenterNeuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary +7

Start: 2020-03-04End: 2021-07-15Updated: 2023-03-10

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

WithdrawnNCT04915144

British Columbia Cancer AgencyCarcinoid Tumor, Gastrinoma, Gastroenteropancreatic Neuroendocrine Tumor +4

Start: 2023-01-15End: 2031-12-31Updated: 2023-02-21

Receptor Radionuclide Therapy With 177Lu-DOTATOC

RecruitingNCT06045260

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSNeuroendocrine Tumors, Paraganglioma, Pheochromocytoma

Start: 2023-09-13End: 2027-01-31Target: 100Updated: 2024-08-13

Dosimetry based PRRT versus standard dose PRRT with Lu-177-DOTATOC in NEN patients- a randomized study; a step towards tailored PRRT.

RecruitingCTIS2024-517240-62-00

Region MidtjyllandNeuroendocrine Tumor

Start: 2024-11-04Target: 100Updated: 2024-11-04

Phase 3

Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors.

RecruitingNCT05387603

Lund University HospitalNeuroendocrine Tumors

Start: 2022-11-01End: 2026-10-01Target: 300Updated: 2025-09-10

Related Papers

Bridging physics and practice: evaluating sensitivity, septal penetration, and detector dead time in terbium-161 gamma-camera imaging